Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Oncology · Chronic Graft-Versus-Host Disease

What is cGVHD After an AML Stem Cell Transplant?

At a Glance

Chronic graft-versus-host disease (cGVHD) is a long-term complication after a stem cell transplant where the donor's immune cells attack your healthy tissues. It requires careful medical management with immunosuppressants to control inflammation, reduce symptoms, and prevent organ damage.

In this answer

3 sections

01

How Does Chronic GVHD Affect the Body?

02

How is Chronic GVHD Treated?

03

Living with Chronic GVHD

Chronic graft-versus-host disease (cGVHD) is a condition that can occur months or even years after an allogeneic stem cell transplant (a transplant using cells from a donor) [1][2]. While acute GVHD typically happens in the first few months and involves rapid inflammation, chronic GVHD is a long-term condition that acts much like an autoimmune disease [1]. In cGVHD, the new immune cells from the donor mistake your body’s healthy tissues as foreign and attack them, causing chronic inflammation and progressive tissue scarring (fibrosis) [1][3].

How Does Chronic GVHD Affect the Body?

Chronic GVHD is a complex disorder that can affect almost any organ [1][2]. It most commonly impacts the following areas:

  • Skin and Nails: The skin is frequently affected. You may notice rashes, changes in skin color, or skin tightening and thickening (sclerosis) [2][4]. Nails can become brittle or ridged.
  • Mouth: Oral symptoms include extreme dryness, sensitivity to spicy or acidic foods, and painful sores or white patches inside the mouth [4][5].
  • Eyes: Severe dry eye is a common hallmark, making your eyes feel gritty, burn, or leading to blurred vision [2][5].
  • Gastrointestinal (GI) Tract: You may experience difficulty swallowing (due to narrowing in the esophagus), unexplained weight loss, nausea, or changes in bowel habits [4][2].
  • Liver: Liver involvement might not cause obvious physical symptoms at first, but it can be detected through routine blood tests that show elevated liver enzymes [6][2].
  • Lungs and Other Organs: cGVHD can seriously affect the lungs, causing a condition called bronchiolitis obliterans—which involves permanent scarring and narrowing of the tiny airways in the lungs. This may start as a persistent dry cough or shortness of breath [7][8]. cGVHD can also impact the joints, muscles, and the gynecological system [9][6].

How is Chronic GVHD Treated?

Managing cGVHD often requires a combination of treatments tailored to your specific symptoms. The goal is to calm the overactive immune system, manage symptoms, and prevent long-term tissue damage [10][3].

  • Systemic Immunosuppressants: The standard first-line treatment is usually oral corticosteroids, such as prednisone, which broadly suppress the donor immune cells [11][12].
  • Targeted Therapies: If symptoms do not improve with steroids, newer targeted drugs may be prescribed. These include medications like ruxolitinib [13][14], belumosudil [15][16], ibrutinib [17][18], or axatilimab [19]. These drugs block specific pathways that cause inflammation and scarring.
  • Topical and Local Treatments: To minimize the side effects of systemic drugs, your care team may prescribe treatments applied directly to the affected area. This includes steroid creams or ointments for the skin [20][6] and prescription anti-inflammatory drops for the eyes [21].

Living with Chronic GVHD

Surviving AML and going through a stem cell transplant is an immense physical and emotional challenge. Being diagnosed with a chronic, potentially organ-damaging disease on top of that can be overwhelming. Living with cGVHD will significantly impact your daily life, making proactive communication with your transplant team critical [22][23].

  • Infection Risk and Precautions: Because systemic treatments for cGVHD work by suppressing your immune system, you are at a significantly higher risk for severe infections [11][12]. You must be vigilant about avoiding sick people, washing your hands, and taking any prescribed preventative antibiotics or antivirals. A fever should be treated as a medical emergency.
  • Report New Symptoms Promptly: Do not wait for your next appointment if you develop new issues, especially a dry cough, shortness of breath, or difficulty eating. Early intervention is crucial to prevent permanent tissue damage [7][6].
  • Practical Daily Management: Small lifestyle adjustments can make a big difference. For instance, rigorous sun protection is vital, as ultraviolet (UV) light can trigger or worsen skin GVHD [20][6]. Adjusting your diet to avoid hard or acidic foods can help manage mouth sores.
  • Routine Screenings: You will require regular check-ups to monitor the health of your organs, which may include specialized dental, eye, and gynecological exams [24][25]. Because cGVHD and its treatments increase the risk of secondary cancers, regular oral cancer screenings are essential [26][25].
  • Psychosocial Support: The emotional toll of this disease is significant. Consider seeking out mental health counseling or patient support groups that specialize in post-transplant survivorship [22][23].

Common questions in this guide

Why does chronic GVHD happen after a stem cell transplant?
After a stem cell transplant using a donor's cells, the new immune system may mistake your body's healthy tissues as foreign. This causes the donor cells to attack your organs, leading to chronic inflammation and tissue scarring.
What are the first signs of chronic GVHD?
Symptoms depend on which organs are affected. Common early signs include skin rashes or thickening, severe dry eyes, extreme dry mouth with sores, difficulty swallowing, or a persistent dry cough.
How is chronic GVHD treated?
The first line of treatment is usually systemic immunosuppressants, such as oral corticosteroids, to calm the overactive immune system. If steroids are not enough, doctors may use newer targeted therapies and localized treatments like steroid creams or specialized eye drops.
What should I do if I get a fever while being treated for cGVHD?
Because treatments for cGVHD suppress your immune system, you are at a high risk for severe infections. A fever should be treated as a medical emergency, and you should contact your doctor or go to the emergency room immediately.
Can chronic GVHD affect my lungs?
Yes, it can cause a serious condition called bronchiolitis obliterans, which involves permanent scarring and narrowing of the small airways. It is critical to report any new dry cough or shortness of breath to your care team right away.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific signs or symptoms should prompt me to call the clinic immediately, rather than waiting for my next appointment?
  2. 2.If I develop a fever, what is the exact temperature at which I need to go to the emergency room?
  3. 3.Who is the primary point of contact for coordinating my care among the different specialists (like dermatologists or eye doctors) I might need to see?
  4. 4.Are there any prophylactic (preventative) medications I should be taking to protect against infections while on immunosuppressants?
  5. 5.What does our timeline for potentially tapering off steroids look like if my symptoms improve?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can You Be Diagnosed with AML with Less Than 20% Blasts?Does AML Chemotherapy Cause Long-Term Heart Problems?Does the Treatment Center Matter for AML Survival?How Do FLT3 and NPM1 Mutations Affect AML?How Do Doctors Assess Fitness for AML Chemotherapy?How is Venetoclax Given for Acute Myeloid Leukemia?How Long Does Chemo Brain Last After AML Treatment?What Are the ELN Risk Categories in AML?What Are AML Induction & Consolidation Therapies?What Are AML Skin and Gum Symptoms? | Inciteful MedWhat Conditions Mimic Acute Myeloid Leukemia?What Does MRD Negative Mean in Acute Myeloid Leukemia?What Is a Day 14 Bone Marrow Biopsy in AML Treatment?

References

References (26)
  1. 1

    Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.

    Zeiser R, Blazar BR

    The New England journal of medicine 2017; (377(26)):2565-2579 doi:10.1056/NEJMra1703472.

    PMID: 29281578
  2. 2

    Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.

    Baumrin E, Loren AW, Falk SJ, et al.

    Journal of the American Academy of Dermatology 2024; (90(1)):1-16 doi:10.1016/j.jaad.2022.12.024.

    PMID: 36572065
  3. 3

    Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.

    Buxbaum NP, Socié G, Hill GR, et al.

    Blood advances 2023; (7(17)):4886-4902 doi:10.1182/bloodadvances.2022007611.

    PMID: 36322878
  4. 4

    MASCC/ISOO Clinical Practice Statement: Management of oral manifestations of chronic graft-versus-host-disease.

    Zadik Y, Raber-Durlacher JE, Epstein JB, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(8)):546 doi:10.1007/s00520-024-08686-x.

    PMID: 39048807
  5. 5

    Oral Complications of Chronic Graft-Versus-Host Disease.

    Fall-Dickson JM, Pavletic SZ, Mays JW, Schubert MM

    Journal of the National Cancer Institute. Monographs 2019; (2019(53)) doi:10.1093/jncimonographs/lgz007.

    PMID: 31425593
  6. 6

    [Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(8)):713-726 doi:10.3760/cma.j.cn121090-20240611-00217.

    PMID: 39307718
  7. 7

    Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.

    Shi CR, Ferreira AL, Kaur M, et al.

    Transplantation and cellular therapy 2024; (30(9S)):S513-S533 doi:10.1016/j.jtct.2024.05.020.

    PMID: 39370234
  8. 8

    Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

    Paz K, Flynn R, Du J, et al.

    Blood 2019; (133(1)):94-99 doi:10.1182/blood-2018-03-839993.

    PMID: 30279226
  9. 9

    Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.

    Bergeron A, Cheng GS

    Clinics in chest medicine 2017; (38(4)):607-621 doi:10.1016/j.ccm.2017.07.003.

    PMID: 29128013
  10. 10

    Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era.

    Vadakkel G, Eng S, Proli A, Ponce DM

    Bone marrow transplantation 2024; (59(10)):1360-1368 doi:10.1038/s41409-024-02370-8.

    PMID: 39080470
  11. 11

    Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival.

    Pidala J, Onstad L, Martin PJ, et al.

    Blood advances 2021; (5(22)):4549-4559 doi:10.1182/bloodadvances.2021005286.

    PMID: 34535015
  12. 12

    Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.

    Baumrin E, Loren AW, Falk SJ, et al.

    Journal of the American Academy of Dermatology 2024; (90(1)):19-36 doi:10.1016/j.jaad.2022.12.023.

    PMID: 36572064
  13. 13

    Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease.

    Sanli NM, Karakuş E

    Hematology, transfusion and cell therapy 2025; (47(3)):103835 doi:10.1016/j.htct.2025.103835.

    PMID: 40354779
  14. 14

    ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.

    Hamad N, Bilmon I, Chee L, et al.

    Internal medicine journal 2023; (53(12)):2319-2329 doi:10.1111/imj.16255.

    PMID: 38014511
  15. 15

    Three-Month Posttransplant Lipidomic Profile Reflects Acute GVHD but Not Chronic GVHD Risk in Allogeneic Stem Cell Recipients.

    Tvedt THA, Qvigstad C, Nezvalova-Henriksen K, et al.

    European journal of haematology 2025; (115(6)):565-573 doi:10.1111/ejh.70011.

    PMID: 40840957
  16. 16

    Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease.

    Ngo D, Tinajero J, Otoukesh S, et al.

    Expert opinion on investigational drugs 2025; (34(5)):391-400 doi:10.1080/13543784.2025.2510667.

    PMID: 40407836
  17. 17

    Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline DDX41-mutated acute myeloid leukemia.

    Uchimura A, Yasuda H, Onagi H, et al.

    Heliyon 2024; (10(2)):e24801 doi:10.1016/j.heliyon.2024.e24801.

    PMID: 38312561
  18. 18

    Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.

    Miklos DB, Abu Zaid M, Cooney JP, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(10)):1876-1887 doi:10.1200/JCO.22.00509.

    PMID: 36608310
  19. 19

    Axatilimab: First Approval.

    Keam SJ

    Drugs 2024; (84(11)):1475-1480 doi:10.1007/s40265-024-02109-1.

    PMID: 39551906
  20. 20

    Survey of European Blood and Marrow Transplant (EBMT) nurses to explore the current topical skin management of chronic cutaneous graft versus host disease in the real-world clinical environment.

    Murray J, Liptrott S, Canesi M, et al.

    European journal of oncology nursing : the official journal of European Oncology Nursing Society 2024; (69()):102547 doi:10.1016/j.ejon.2024.102547.

    PMID: 38467081
  21. 21

    Frequency of Topical Immunomodulatory and Immunosuppressive Therapies for Ocular Chronic Graft-versus-Host Disease.

    Koca DS, Dietrich-Ntoukas T

    Journal of clinical medicine 2024; (13(16)) doi:10.3390/jcm13164728.

    PMID: 39200870
  22. 22

    Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

    Kiene S, Albrecht M, Theurich S, et al.

    The Cochrane database of systematic reviews 2024; (11()):CD010189 doi:10.1002/14651858.CD010189.pub3.

    PMID: 39508306
  23. 23

    [Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].

    Huang SQ, Huang RH, Quan Y, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(1)):54-61 doi:10.3760/cma.j.cn121090-20231008-00162.

    PMID: 38527839
  24. 24

    Secondary Oral Cancer after Systemic Treatment of Hematological Malignancies and Oral GVHD: A Systematic Review.

    Janowiak-Majeranowska A, Osowski J, Mikaszewski B, Majeranowski A

    Cancers 2022; (14(9)) doi:10.3390/cancers14092175.

    PMID: 35565303
  25. 25

    Prioritising gynaecological care in post-haematopoietic stem cell transplant patients.

    Jain A, Pandurangi M, Jayaraman D, Vembu R

    BMJ case reports 2025; (18(1)) doi:10.1136/bcr-2024-261534.

    PMID: 39809484
  26. 26

    Multiple and Recurrent Squamous Cell Carcinoma of the Oral Cavity After Graft-Versus-Host Disease.

    Weng X, Xing Y, Cheng B

    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2017; (75(9)):1899-1905 doi:10.1016/j.joms.2017.02.012.

    PMID: 28322198

This page provides educational information about chronic graft-versus-host disease (cGVHD) and its management. It is not a substitute for professional medical advice, diagnosis, or treatment from your transplant team.

Get notified when new evidence is published on Acute myeloid leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.